Zeria Pharmaceutical has a rich history in producing chondroitin products, going back as early as 1959 when it launched its very first Chondroitin pharmaceutical product. Since its inception, Zeria has been at the forefront of Chondroitin research and development, pioneering innovative formulations that address diverse health concerns.
1955 | Establishment of Zeria Yakusho Kenkyusho Co., Ltd. (former name for Zeria Pharmaceutical Co., Ltd.) in Japan |
1959 | Launch of Zeria’s first Chondroitin pharmaceutical product |
2006 | Chondroitin product range sales hit JPY 5 billion |
2010 | Acquisition of ZPD A/S (formerly known as Biofac Esbjerg A/S), a Denmark-based manufacturer and developer of glycosaminoglycan Chondroitin Sulfate sodium, as a subsidiary of the Zeria group |
With Zeria’s deep understanding of Chondroitin and its potential as a pharmaceutical product, the company consistently explores innovative business solutions to further its expansion in this field. Placing top priority in securing the highest-possible quality of its raw materials, Zeria acquired ZPD A/S (formerly known as Biofac Esbjerg A/S) in 2010, a manufacturer and developer of glycosaminoglycan Chondroitin Sulfate sodium, which now serves as an independent subsidiary under the Zeria group, making it possible for Zeria to achieve stable procurement of high-quality Chondroitin materials in its production of Chondroitin pharmaceutical products.
The Denmark-based production facility adheres to stringent regulations stipulated by the European Union, executing rigorous quality control measures throughout its entire manufacturing process from upstream to downstream, enabling full traceability to ensure the efficacy and safety of its products.
Drug Manufacturing License (Danish Medicines Agency)
GMP certification for Chondroitin Sulfate Sodium
HACCP Principles
Food Authorisation (Danish Veterinary and Food Administration)
Approved for handling Cat. III by Danish Veterinary and Food Administration, according to EC No. 1069/2009
Registration as a Feed Manufacturer - regulation (EC) No. 183/2005
Authorised according to EU regulation 852/2004 + 853/2004 and its amendment EU 2016/355
Accreditation Certificate of Foreign Drug Manufacturer (AG20400038) (Japan)
Registered with the US FDA pursuant to the Federal Food Drug and Cosmetic Act
In accordance with Zeria’s spirit of manufacturing, the company continuously strives to further improve quality and reliability through an integrated system that encompasses functions ranging from development to production and distribution.
Zeria has built an optimal production structure underpinned by its 4 domestic and 3 overseas production bases, through which it makes its utmost efforts to manufacture high quality and highly reliable products.
The Tsukuba Plant, which produces a wide range of products including Zeria's Chondroitin product range, has obtained certification for Good Manufacturing Practice (GMP) for the category of dietary supplements, as well as ISO 14001, the international standard for environmental management systems.
As a comprehensive healthcare company, Zeria is committed to the development of pharmaceutical products that contribute to the health of people around the world, pursuing the highest quality in all of its corporate activities and enhancing the quality of life of its customers and stakeholders.